Ixchel On Last Legs With Antitrust Claims Against Biogen

By Bryan Koenig (January 26, 2018, 7:59 PM EST) -- A California federal judge on Thursday gave Ixchel Pharma LLC one last chance to accuse Biogen Inc. of entering into an anti-competitive agreement with another company and undermining Ixchel's development of a treatment for a rare neuromuscular disease, holding the latest complaint is just as deficient as its predecessor.

U.S. District Judge William B. Shubb said Ixchel has already twice amended its complaint, and he concluded that further amendments to its first four claims "would be futile." The only reason Judge Shubb allowed Ixchel a single additional bite at the apple, he said in dismissing the company's second amended complaint, is...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Judge Analytics

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!